Business Wire

CA-XPANSIV-CBL-HOLDING

27.7.2020 15:02:13 CEST | Business Wire | Press release

Share
XCHG Signs First XSignals Customers, Providing Actionable ESG Insights and Market Benchmarks

XCHG , the global marketplace for Intelligent Commodities™, today announced the launch of XSignals , a component of the company’s multi-sided platform that offers unprecedented clarity in the pricing and analysis of digital, ESG-inclusive commodities (d-ESGc ). These price signals—reported directly from open market activity—become benchmarks that enable vital ESG factors to be calculated into global trade.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005224/en/

XSignals' initial customers include leading firms engaged in providing trading services to sellers and buyers of digital environmental commodities like Renewable Energy Certificates and Carbon Offsets, with a pipeline of customers from industries making long-term environmental commitments, such as the aviation industry’s CORSIA accord.

“The markets we serve are incredibly dynamic, and our customers need to know where value is being created, as reflected in real-time prices,” said Andy Bose, Head of Ecosystems and Data Partnerships for XCHG. “With the launch of our XSignals platform, we provide an unparalleled understanding of the forces moving commodities markets, giving our customers comprehensive information to inform better decisions."

Inclusive of a broad range of asset classes and offerings, XSignals provides timely, transparent information to support trading, compliance, and risk-management decisions. XSignals translates ESG spot market price data into high-quality reference products, enabling global markets to accurately price ESG factors.

“Our aim in launching XSignals is to enhance the market's understanding of price and value for the broad range of environmental products transacted on our exchange,” Bose said. “We’re offering unique insight into where prices are coming from, empowering a deeper understanding of where value will be in the future.”

XCHG’s first product offerings include market data—trade orders and consummated transactions—in US RECs and international carbon from the company’s spot exchange, CBL Markets . XSignals provides daily data on price, volume, time, market depth, and other key indicators that offer real-time insight into value, as reflected in the marketplace. XSignals also offers access to a historical data set that covers the last 30 months of transactions.

“In order for the global economy to transition to a sustainable trajectory, indicative price signals for ESG factors in food, energy, and materials are needed to direct capital flows over time,” said XCHG CEO Joe Madden. “XSignals provides the foundation for this transition through the consistent, reliable representation of objective value for ESG factors in commodity pricing.”

XCHG plans to deepen the XSignals offering with more capabilities, including tools for data analysis and visualization, allowing customers to both self-serve and take advantage of XCHG’s understanding of how that data will be of maximum value.

“XSignals is another step toward delivering on our mission of more accurately valuing the commodities at the base of the global economy in the century ahead,” said Madden.

About XCHG

Xpansiv CBL Holding Group (XCHG) is the world’s first commodity marketplace built for a data-rich, resource-constrained world. We bring transparency to global markets through innovative, ESG-inclusive commodity products and price information. XCHG.net

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye